Huprines for alzheimer's disease drug development

Expert Opinion on Drug Discovery

Volumn 3, Issue 1, 2008, Pages 65-81

  Muñoz Torrero, Diego ^a   Camps, Pelayo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

13 amidohuprine; Acetylcholinesterase inhibitor; Alzheimer's disease; Huprine; Huprine tacrine heterodimer; Neuroprotective agent; Prion protein antiaggregating agent

Indexed keywords

13 AMIDOHUPRINE DERIVATIVE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HETERODIMER; HUPERZINE A; HUPRINE DERIVATIVE; HUPRINE X; HUPRINE Y; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COMPLEX FORMATION; DISEASE COURSE; DRUG DESIGN; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOSELECTIVITY; EVIDENCE BASED MEDICINE; HUMAN; LIVER TOXICITY; MEDICAL LITERATURE; MOLECULAR HYBRIDIZATION; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; X RAY CRYSTALLOGRAPHY;

EID: 38849116319     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.1.65     Document Type: Review

References (97)

1. Wimo A, Winblad B, Aguero Torres H, et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17:63-7
2. Mount C, Dowton C. Alzheimer disease: progress or profit? Nat Med 2006;12:780-4
3. Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Ann Rev Med 2006;57:513-33
4. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977:189
5. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17
6. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-6
7. Klafki H-W, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006;129:2840-55
8. Castellani RJ, Zhu X, Lee H-G, et al. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother 2007;7:473-85
9. Lee H-G, Zhu X, Nunomura A, et al. Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 2006;3:75-80
10. Sambamurti K, Suram A, Venugopal C, et al. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 2006;81-91
11. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's diasese: progress and problems on the road to therapeutics. Science 2002;297:353-6
12. Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 2006;3:71-3
13. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007;6:341-2
14. Saido TC, Iwata N. Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res 2006;54:235-53
15. Skovronsky DM, Lee VM-Y, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Ann Rev Pathol Mech Dis 2006;1:151-70
16. Tschäpe J-A, Hartmann T. Therapeutic perspectives in Alzheimer's disease. Recent Pat CNS Drug Discov 2006;1:119-27
17. Verhoeff NPLG. Acetylcholinergic neurotransmission and the β-amyloid cascade: implications for Alzheimer's disease. Expert Rev Neurother 2005;5:277-84
18. Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 2004;10:3111-19
19. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(Suppl 1):S12-S18
20. Colombres M, Sagal JP, Inestrosa NC. Overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. Curr Pharm Des 2004;10:3121-30
21. Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 2006;20(Suppl 1):S8-S11
22. Mori E, Hashimoto M, Krishnan K, Doraiswamy PM. What constitutes clinical evidence for neuroprotection in Alzheimer disease. Support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 2006;20(Suppl 1):S19-S26
23. Sabbagh MN, Farlow MR, Relkin N, Beach TG. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? Alzheimer's Dementia 2006;2:118-25
24. Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005;162:676-82
25. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991;253:872-9
26. Wermuth CG. The practice of medicinal chemistry. London: Academic Press, 2003
27. Proctor GR, Harvey AL. Synthesis of tacrine analogues and their structure-activity relationships. Curr Med Chem 2000;7:295-302
28. Kozikowski AP, Tückmantel W. Chemistry, pharmacology and clinical efficacy of the Chinese nootropic agent huperzine A. Acc Chem Res 1999;32:641-50
29. Tang XC, He XC, Bai DL. Huperzine A: a novel acetylcholinesterase inhibitor. Drugs Future 1999;24:647-63
30. Gregor VE, Emmerling MR, Lee C, Moore CJ. The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex) derivatives. Bioorg Med Chem Lett 1992;2:861-4
31. Raves ML, Harel M, Pang Y-P, et al. 3D structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol 1997;4:57-63
32. Harel M, Schalk I, Ehret-Sabatier L, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acerylcholinesterase. Proc Natl Acad Sci USA 1993;90:9031-5
33. Pang Y-P, Quiram P, Jelacic T, et al. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J Biol Chem 1996;271:23646-9
34. Pang Y-P, Hong F, Quiram P, et al. Synthesis of alkylene linked bis-THA and alkylene linked benzyl-THA as highly potent and selective inhibitors and molecular probes of acetylcholinesterase. J Chem Soc Perkin Trans I 1997;171-6
35. Carlier PR, Han YF, Chow ES-H, et al. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg Med Chem 1999;7:351-7
36. Harel M, Quinn DM, Nair HK, et al. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. J Am Chem Soc 1996;118:2340-6
37. Doucet-Personeni C, Bentley PD, Fletcher RJ, et al. A structure-based design approach to the development of novel, reversible AChE inhibitors. J Med Chem 2001;44:3203-15
38. Dvir H, Wong DM, Harel M, et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: kinetic and molecular dynamics correlates. Biochemistry 2002;41:2970-81
39. Camps P, El Achab R, Font-Bardia M, et al. Easy synthesis of 7-alkylbicyclo[3.3.1] non-6-en-3-ones by silical gel-promoted fragmentation of 3-alkyl-2-oxaadamant-1-yl mesylates. Tetrahedron 1996;52:5867-80
40. Badia A, Baños JE, Camps P, et al. Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. Bioorg Med Chem 1998;6:427-40
41. Camps P, Contreras J, Morral J, et al. Synthesis of an 11-unsubstituted analogue of (±)-huperzine A. Tetrahedron 1999;55:8481-96
42. Camps P, Contreras J, El Achab R, et al. New syntheses of rac-huperzine A and its rac-7-ethyl-derivative. Evaluation of several huperzine A analogues as acetylcholinesterase inhibitors. Tetrahedron 2000;56:4541-53
43. Camps P, Muñoz-Torrero D. Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Mini Rev Med Chem 2001;1:163-74
44. Camps P, Gómez E, Muñoz-Torrero D, et al. Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors. J Med Chem 2001;44:4733-6
45. Camps P, El Achab R, Görbig DM, et al. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J Med Chem 1999;42:3227-42
46. Steinberg GM, Mednick ML, Maddox J, et al. A hydrophobic binding site in acetylcholinesterase. J Med Chem 1975;18:1056-61
47. Camps P, El Achab R, Morral J, et al. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J Med Chem 2000;43:4657-66
48. Savini L, Campiani G, Gaeta A, et al. Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem Lett 2001;11:1779-82
49. Camps P, Contreras J, Font-Bardia M, et al. Enantioselective synthesis of tacrine-huperzine A hybrids. Preparative chiral MPLC separation of their racemic mixtures and absolute configuration assignments by X-ray diffraction analysis. Tetrahedron: Asymmetry 1998;9:835-49
50. Camps P, Cusack B, Mallender WD, et al. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000;57:409-17
51. Alcalá MM, Vivas NM, Hospital S, et al. Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybrids. Neuropharmacology 2003;44:749-55
52. Wang R, Yan H, Tang X-C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006;27:1-26
53. Perry EK, Smith CJ, Court JA, et al. Interaction of 9-amino- 1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neurosci Lett 1988;91:211-16
54. Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Mol Brain Res 1998;62:131-40
55. Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989;24:276-85
56. Zhang HY, Yan H, Tang XC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-α in intracerebroventricular β-amyloid (1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004;360:21-4
57. Roman S, Vivas NM, Badia A, Clos MV. Interaction of a new potent anticholinesterasic compound (±)huprine X with muscarinic receptors in rat brain. Neurosci Lett 2002;325:103-6
58. Alcaá MM, Maderuelo A, Vivas NM, et al. Effects of (±)-huprine Y and (±)-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors. Neurosci Lett 2005; 379:106-9
59. Ved HS, Koenig ML, Dave JR, Doctor BP. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport 1997;8:963-8
60. [3H]MK-801 binding in rat cerebral cortex. Neurosci Lett 1999;272:21-4
61. Canudas AM, Pubill D, Sureda FX, et al. Neuroprotective effects of (±)-huprine Y on in vitro and in vivo models of excitotoxicity damage. Exp Neurol 2003;180:123-30
62. Jordá EG, Verdaguer E, Jiménez A, et al. (±)-Huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration. J Alzheimer Dis 2004;6:577-83
63. Alvarez A, Bronfman F, Pérez CA, et al. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides. Neurosci Lett 1995;201:49-52
64. Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996;16:881-91
65. Alvarez A, Alarcón R, Opazo C, et al. Stable complexes involving acerylcholinesterase and amyloid-β-peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 1998;18:3213-23
66. Reyes AE, Chacón MA, Dinamarca MC, et al. Acetylcholinesterase-Aβ complexes are more toxic than Aβ fibrils in rat hippocampus. Effect on rat β-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol 2004;164:2163-74
67. De Ferrari GV, Canales MA, Shin I, et al. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 2001;40:10447-57
68. Pan KM, Baldwin M, Nguyen J, et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993;90:10962-6
69. c) promotes β-amyloid plaque formation. Neurobiol Aging 2005;26:1177-82
70. Armstrong RA, Lantos PL, Cairns NJ. Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt-Jakob disease. Neuropathology 2001;21:266-71
71. Pera M, Román S, Ratia M, et al. Acetylcholinesterase triggers the aggregation of PrP 106-126. Biochem Biophys Res Commun 2006;346:89-94
72. Bartolini M, Bertucci C, Cavrini V, Andrisano V. β-Amyloid aggregation induction by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003;65:407-16.
73. Jiang H, Luo X, Bai D. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional Chinese medicine origin for the treatment of Alzheimer's disease. Curr Med Chem 2003;10:2231-52
74. Farlow M, Gracon SI, Heshey LA, et al. A controlled trial of tacrine in Alzheimer's patients. JAMA 1992;268:2523-9
75. Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 1993;46:13-20
76. Nassar A-EF, Kamel AM, Clarimont C. Improving the decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discov Today 2004;9:1055-64
77. Ma XC, Xin J, Wang HX, et al. Acute effects of huperzine A and tacrine on rat liver. Acta Pharmacol Sin 2003;24:247-50
78. Medichem SA. Nuevos compuestos aminopiridínicos policíclicos inhibidores de acetilcolinesterasa, procedimiento para su preparación y su utilización. ES2100129 (1995); Novel polycyclic aminopyridine compounds as acetylcholinesterase inhibitors, preparation process and use thereof. WO97/13754 (1997)
79. Dvir H, Jiang HL, Wong DM, et al. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. Biochemistry 2002;41:10810-18
80. Camps P, Gómez E, Muñoz-Torrero D, et al. Synthesis of diastereomeric 13-amido-substituted huprines as potential high affinity acetylcholinesterase inhibitors. Tetrahedron 2003;59:4143-51
81. Camps P, Gómez E, Muñoz-Torrero D. Synthesis of 13-acylamino-huprines: different behavior of diastereomeric 13-methanesulfonamido-huprines on PPA-mediated hydrolysis. Tetrahedron 2004;60:5423-31
82. Camps P, Gómez E, Muñoz-Torrero D, et al. Binding of 13-amidohuprines to acetylcholinesterase: exploring the ligand-induced conformational change of the Gly117-Gly118 peptide bond in the oxyanion hole. J Med Chem 2006;49:6833-40
83. Fuxreiter M, Warshel A. Origin of the catalytic power of acetylcholinesterase: computer simulation studies. J Am Chem Soc 1998;120:183-94
84. Muñoz-Torrero D, Camps P. Dimeric and hybrid anti-Alzheimer drug candidates. Curr Med Chem 2006;13:399-422
85. Muñoz-Ruiz P, Rubio L, García-Palomero E, et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J Med Chem 2005;48:7223-33
86. Bolognesi ML, Andrisano V, Bartolini M, et al. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-β aggregation. J Med Chem 2005;48:24-7
87. Rosini M, Andrisano V, Bartolini M, et al. Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 2005;48:360-3
88. Belluti F, Rampa A, Piazzi L, et al. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced β-amyloid aggregation. J Med Chem 2005;48:4444-56
89. Cavalli A, Bolognesi ML, Capsoni S, et al. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed 2007;46:3689-92
90. Bolognesi ML, Banzi R, Bartolini M, et al. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J Med Chem 2007;50:4882-97
91. Piazzi L, Cavalli A, Belluti F, et al. Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl] phenyl}-6,7-dimethoxy-2H-2-chromemone (AP2238) derivatives. J Med Chem 2007;50:4250-4
92. 1-42 aggregation for Alzheimer's disease therapeutics. Bioorg Med Chem 2007;15:6596-607
93. Hu M-K, Wu L-J, Hsiao G, Yen MH. Homodimeric tacrine congeners as acetylcholinesterase inhibitors. J Med Chem 2002;45:2277-82
94. Rodriguez-Franco MI, Fernández-Bachiller MI, Pérez C, et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 2006;49:459-62
95. Camps P, Formosa X, Muñoz-Torrero D, et al. Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem 2005;48:1701-4
96. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2005;9:1-24
97. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004;50:433-40